Abbott Laboratories (ABT) : Vestor Capital scooped up 2,869 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 9, 2016. The investment management firm now holds a total of 234,926 shares of Abbott Laboratories which is valued at $10,576,369.Abbott Laboratories makes up approximately 2.89% of Vestor Capital’s portfolio.
Other Hedge Funds, Including , Atlanta Capital Group reduced its stake in ABT by selling 217 shares or 2.14% in the most recent quarter. The Hedge Fund company now holds 9,940 shares of ABT which is valued at $447,499. Abbott Laboratories makes up approx 0.10% of Atlanta Capital Group’s portfolio.Columbia Asset Management reduced its stake in ABT by selling 2,535 shares or 13.37% in the most recent quarter. The Hedge Fund company now holds 16,425 shares of ABT which is valued at $739,946. Abbott Laboratories makes up approx 0.25% of Columbia Asset Management’s portfolio.Regal Investment Advisors reduced its stake in ABT by selling 198 shares or 2.83% in the most recent quarter. The Hedge Fund company now holds 6,808 shares of ABT which is valued at $308,130. Abbott Laboratories makes up approx 0.08% of Regal Investment Advisors’s portfolio.Intrust Bank Na boosted its stake in ABT in the latest quarter, The investment management firm added 2,547 additional shares and now holds a total of 21,948 shares of Abbott Laboratories which is valued at $986,563. Abbott Laboratories makes up approx 0.39% of Intrust Bank Na’s portfolio.Security National Trust Co boosted its stake in ABT in the latest quarter, The investment management firm added 5 additional shares and now holds a total of 30,555 shares of Abbott Laboratories which is valued at $1,319,059. Abbott Laboratories makes up approx 0.47% of Security National Trust Co’s portfolio.
Abbott Laboratories closed down -0.24 points or -0.53% at $44.68 with 86,30,316 shares getting traded on Wednesday. Post opening the session at $45.14, the shares hit an intraday low of $44.44 and an intraday high of $45.14 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.